Understanding the Hepatotoxicity of Fasiglifam (TAK-875)
- 15 February 2021
- Resource Type: Posters, Toxicology & Safety
Fasiglifam (TAK-875) is a GPR40 agonist which was developed for the treatment of type 2 diabetes. However, during Phase III clinical trials, it was withdrawn due to adverse liver effects.
In this poster, we focus on:
- deciphering the mechanism of hepatotoxicity of fasiglifam (TAK-875)
- understanding the impact of plasma protein binding and mitochondrial effects by fasiglifam using the Seahorse flux analyser platform
Read our poster to learn more about our research!
Sounds interesting?
Enter your details below to continue reading…
